Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma.

Clinical endocrinology - 1 Jul 2014

Zou Minjing, BinHumaid Faisal S, Alzahrani Ali S, Baitei Essa Y, Al-Mohanna Futwan A, Meyer Brian F, Shi Yufei

Abstract excerpt

OBJECTIVE: 1α, 25(OH)2 D3 (calcitriol), the active form of vitamin D, has been shown to exert antiproliferative effects in many cancers. Overexpression of CYP24A1, the primary vitamin D-inactivating enzyme, is also observed in a variety of human cancers, thus potentially neutralizing the antitumour effect of 1α, 25(OH)2 D3. This study investigates the expression of CYP24A1 and the effect of BRAF(V600E) on its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to In Vitro Techniques

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Vitamin D3 24-Hydroxylase

Source

Identifiers

PMID: 24382015
DOI: 10.1111/cen.12396

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma.PMID 24382015Read ↗

Vitamin D-neutralizing CYP24A1 expression, oncogenic mutation states and histological findings of human papillary thyroid cancer.Semantic proximity Read ↗

Oestrogen receptor alpha in papillary thyroid carcinoma: association with clinical features and BRAFV600E mutation.Semantic proximity Read ↗

Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model.Semantic proximity Read ↗

Influence of the BRAF V600E Mutation on Expression of Vascular Endothelial Growth Factor in Papillary Thyroid CancerSemantic proximity Read ↗

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).Semantic proximity Read ↗

Impact of molecular alterations of BRAF in the pathogenesis of thyroid cancerSemantic proximity Read ↗

Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.Semantic proximity Read ↗

[Studies on the BRAF T1799A gene mutation in papillary thyroid cancer: an example of translational medicine].Semantic proximity Read ↗

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.Semantic proximity Read ↗

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.Semantic proximity Read ↗

Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.Semantic proximity Read ↗

BRAF-Oncogene-Induced Senescence and the Role of Thyroid-Stimulating Hormone Signaling in the Progression of Papillary Thyroid Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.